Skip to main content
Premium Trial:

Request an Annual Quote

Visiopharm, ISENET Partner to Promote Tissue Microarray Workflow


Visiopharm and Integrated Systems Engineering have agreed to comarket their products to researchers using tissue microarrays.

Integrated Systems Engineering, or ISENET, is a Milan-based company that offers a menu of tissue microarraying instruments called Galileo TMA CK. Visiopharm is a Hørsholm, Denmark-based firm that provides software for quantitative digital pathology. Visiopharm sells an analysis tool called Arrayimager that can produce a report based on data obtained from Galileo TMA CK systems and manage data, allowing users to search results based on donor identity, specific biomarkers, and other results.

Pasquale De Blasio, CEO of ISENET, said in a statement that the two firms aim to "provide the research and diagnostic communities with a TMA solution focused on quality, data integrity and results."

Both European companies maintain distributors in most major regional markets. Visiopharm has a partnership with Olympus to distribute Arrayimager in North and South America and Asia. ISENET relies on a number of distributors to reach customers in different European countries and also sells its systems direct worldwide from its headquarters in Italy.

Further details of the partnership were not discussed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.